Biogen Shares Drop Following Mid-Stage Trial Results for Alzheimer’s Drug
Biogen shares declined after releasing mid-stage trial results for its novel Alzheimer's drug diranersen. While the data showed early signs of efficacy, which patient advocates praised, the stock fell in response to the mixed outcomes.
Topics: Alzheimer's drug Biogen Ionis Pharmaceuticals Phase 2 study